Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
PLoS One ; 6(1): e16346, 2011 Jan 27.
Artículo en Inglés | MEDLINE | ID: mdl-21298004

RESUMEN

We have investigated the immunological and metabolomic impacts of Cry1Ab administration to mice, either as a purified protein or as the Cry1Ab-expressing genetically modified (GM) MON810 maize. Humoral and cellular specific immune responses induced in BALB/cJ mice after intra-gastric (i.g.) or intra-peritoneal (i.p.) administration of purified Cry1Ab were analyzed and compared with those induced by proteins of various immunogenic and allergic potencies. Possible unintended effects of the genetic modification on the pattern of expression of maize natural allergens were studied using IgE-immunoblot and sera from maize-allergic patients. Mice were experimentally sensitized (i.g. or i.p. route) with protein extracts from GM or non-GM maize, and then anti-maize proteins and anti-Cry1Ab-induced immune responses were analyzed. In parallel, longitudinal metabolomic studies were performed on the urine of mice treated via the i.g. route. Weak immune responses were observed after i.g. administration of the different proteins. Using the i.p. route, a clear Th2 response was observed with the known allergenic proteins, whereas a mixed Th1/Th2 immune response was observed with immunogenic protein not known to be allergenic and with Cry1Ab. This then reflects protein immunogenicity in the BALB/c Th2-biased mouse strain rather than allergenicity. No difference in natural maize allergen profiles was evidenced between MON810 and its non-GM comparator. Immune responses against maize proteins were quantitatively equivalent in mice treated with MON810 vs the non-GM counterpart and no anti-Cry1Ab-specific immune response was detected in mice that received MON810. Metabolomic studies showed a slight "cultivar" effect, which represented less than 1% of the initial metabolic information. Our results confirm the immunogenicity of purified Cry1Ab without evidence of allergenic potential. Immunological and metabolomic studies revealed slight differences in mouse metabolic profiles after i.g. administration of MON810 vs its non-GM counterpart, but no significant unintended effect of the genetic modification on immune responses was seen.


Asunto(s)
Inmunidad Adaptativa , Anticuerpos/administración & dosificación , Proteínas Bacterianas/administración & dosificación , Endotoxinas/administración & dosificación , Proteínas Hemolisinas/administración & dosificación , Metabolómica , Zea mays/inmunología , Alérgenos , Animales , Anticuerpos/inmunología , Toxinas de Bacillus thuringiensis , Proteínas Bacterianas/inmunología , Proteínas Bacterianas/metabolismo , Endotoxinas/inmunología , Endotoxinas/metabolismo , Proteínas Hemolisinas/inmunología , Proteínas Hemolisinas/metabolismo , Inmunidad Celular , Inmunidad Humoral , Metabolismo , Ratones , Ratones Endogámicos BALB C , Extractos Vegetales/inmunología , Extractos Vegetales/metabolismo , Plantas Modificadas Genéticamente , Células Th2/inmunología , Zea mays/metabolismo
2.
Int Arch Allergy Immunol ; 143(1): 10-20, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17191005

RESUMEN

BACKGROUND: CpG oligonucleotides might offer an alternative to conventional immunotherapy in preventing and potentially reversing Th2-biased immune deregulation which leads to allergy. However, non-invasive ways of administration, especially in peanut-allergic patients, should be explored. METHODS: One hundred micrograms of whole peanut protein extract (PE) alone, or mixed with cholera toxin (CT, 50 microg) plus CpG (100 microg) as adjuvant, was applied on intact skin of mice (40 min, twice). Initiation of an immune response was monitored by detection of specific antibodies in sera. The effect of this pretreatment on a further oral sensitization by PE was then evaluated by assaying antibodies and cytokines specific for PE and purified allergens. Cytokine production in liver 40 min after skin application was also assayed. RESULTS: Two brief skin applications of PE alone highly potentiated further oral sensitization, as demonstrated by very intense specific IgE, IL-4 and IL-5 productions. Conversely, skin pretreatment with PE and CT + CpG efficiently prevented further sensitization via gastro-intestinal exposure. In both cases, the specificity of the antibodies and cytokines was the same as in control mice. CT + CpG treatment allowed the rapid production of IL-12 and TGFbeta in liver and of specific IgG2a in sera, suggesting the activation of Th1 and/or regulatory T cells. CONCLUSIONS: Oral sensitization to peanut is highly enhanced by a previous short exposure of allergens to intact skin. Conversely, the use of CT + CpG adjuvant for skin application efficiently prevents further oral sensitization. The potential of such treatment in specific immunotherapy needs to be evaluated.


Asunto(s)
Toxina del Cólera/farmacología , Oligodesoxirribonucleótidos/farmacología , Hipersensibilidad al Cacahuete/terapia , Piel/inmunología , Administración Oral , Animales , Femenino , Inmunoglobulina A/análisis , Inmunoglobulina E/sangre , Inmunoglobulina G/sangre , Inmunoglobulina G/clasificación , Interleucina-4/biosíntesis , Interleucina-5/biosíntesis , Hígado/inmunología , Ratones , Ratones Endogámicos BALB C , Hipersensibilidad al Cacahuete/etiología , Extractos Vegetales/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA